查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947953

Eculizumab市场依适应症、通路、最终用户及病患年龄组别划分，全球预测，2026-2032年

Eculizumab Market by Indication, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Eculizumab市场价值将达到 43.5 亿美元，到 2026 年将成长至 45.3 亿美元，复合年增长率为 5.19%，到 2032 年将达到 62.1 亿美元。

关键市场统计数据
基准年 2025 43.5亿美元
预计年份：2026年 45.3亿美元
预测年份 2032 62.1亿美元
复合年增长率 (%) 5.19%

关于Eculizumab在复杂补体依赖性疾病中不断演变的作用的执行性引言

Eculizumab已成为补体介导疾病领域的生物製药，本概要概述了其临床意义、商业性趋势和策略转折点。本文重点阐述了其作为末端补体（C5）抑制剂的作用机制，并着重介绍了其临床应用如何从血液学扩展到神经学，从而形成超越传统专科界限的新型应用模式。理解这一背景将有助于相关人员更清晰地理解该药物在复杂疾病治疗中的重要性，并解读后续分析。

对推动Eculizumab治疗领域快速变革的科学、监管与竞争因素进行深入分析

近期科学进展、治疗选择的多样化以及监管环境的变化如何重塑Eculizumab的竞争格局和临床格局

由于科学创新、竞争对手的涌入以及监管环境的不断变化，Eculizumab的市场环境正在经历变革性变化。补体生物学的进展、长效C5抑制剂以及针对近端补体成分的药物的出现，正在改变临床决策，带来不同的给药频率、给药途径和安全性特征。因此，临床医师在选择治疗慢性补体依赖性疾病的方案时，会更谨慎地权衡治疗效益与治疗负担。

评估美国计划于 2025 年实施的关税政策变化对高价值生物製药的价值链、生产製造和患者获取途径的累积影响

新增或提高关税可能会对整个生物製药价值链产生连锁反应，影响原材料采购、契约製造成本以及Eculizumab等治疗药物的物流。关税导致的成本上涨通常首先表现为活性药物成分和特殊耗材采购成本的增加，迫使製造商重新评估其供应基础并考虑近岸外包策略。随着时间的推移，这些压力可能导致製造商加速投资国内生产能力，并采取合约避险策略来稳定投入成本。

整合适应症、通路、终端用户和患者群体特征等趋势的策略性细分洞察，有助于制定有针对性的商业策略。

Eculizumab市场涵盖多种适应症，每种适应症都有其独特的临床路径和治疗模式。非典型溶血性尿毒症候群 (aHUS) 的治疗分为第一线和第二线治疗，早期疗育和难治性病例需要不同的诊断流程和支持。重症肌无力和视神经脊髓炎频谱障碍均存在不可治疗和难治性亚组，通常需要具有神经科专业知识的医师进行细緻的临床判断。阵发性睡眠性血尿症也同样分为第一线和二线治疗组，既往输血史和血栓风险会影响治疗的紧迫性和监测频率。

影响市场准入、监管合规性和商业性可行性的区域优先事项和差异化策略（美洲、欧洲、中东和非洲、亚太地区）

区域趋势对Eculizumab疗法的应用有显着影响，不同的法规结构、报销机制和医疗基础设施都会影响其普及程度。在美洲，强调罕见疾病治疗可及性的政策和完善的专科医疗网络鼓励在三级医疗中心集中使用依库珠单抗，而支付方谈判和批量采购协议则决定了其商业性条款。同时，欧洲、中东和非洲（EMEA）地区的法规环境各不相同，包括各国不同的卫生技术评估（HTA）流程、报销机构和医院容量。因此，确保依库珠单抗被纳入药品目录需要量身定制的实证依据和弹性价格设定策略。

公司定位、伙伴关係策略和生命週期管理方法塑造了Eculizumab及相关补体标标靶治疗的竞争格局。

主要企业的策略体现了双重重点：既要保护现有业务，又要投资下一代资产和策略合作。药物研发公司致力于透过拓展适应症、进行病患支援专案和进行长期安全性研究来延长药物生命週期，从而提升临床价值，同时利用其生产规模和全球分销网络来维持供应的可靠性。同时，致力于研发其他补体路径标靶或长效C5抑制剂的公司则采取了互补策略，包括共同开发契约、授权协议以及针对特定未满足医疗需求族群的标靶临床项目。

为产业领导者提供切实可行的建议，以保障补充疗法领域的市场准入、优化商业性绩效并加速以病人为中心的创新

产业领导者应优先考虑三大支柱：拓展临床证据、增强供应链韧性、与支付者共用价值。首先，投资于有针对性的真实世界证据项目，以证明关键适应症和亚群的功能性疗效。这些证据将有助于加强报销谈判和临床应用，尤其是在出现疗效比较问题时。其次，透过原材料供应商多元化、探索本地製造伙伴关係关係以及实施库存策略来降低供应链风险，从而减少关税和物流中断的影响。这些营运措施将确保医院和专科诊所的持续服务。

采用严谨的混合调查方法，结合关键相关人员的访谈、二手证据的综合分析、背景政策分析，得出可靠的结论。

本研究采用混合方法，结合结构化的初步研究、全面的二手研究、情境化的监管审查。初步研究包括对血液科和神经科专家、医院药房主任、专科诊所主任和支付方进行深度访谈，以了解实际治疗路径、就医障碍和通路偏好。这些访谈，以及与供应链和生产专家的讨论，帮助我们了解了物流、低温运输要求和产能限制。

审查报告重点强调了维持补体抑制剂治疗患者临床可近性和长期价值的策略重点。

总之，Eculizumab在快速发展的治疗领域中仍然是一种重要的临床治疗方法，该领域的特点是科学创新、监管预期变化和竞争日益激烈。新进入者的出现、替代性补体标靶机制的出现以及支付方期望的转变，都要求我们采取积极主动、基于实证医学的生命週期管理方法。那些能够将可靠的真实世界证据生成、强大的生产能力和以地域为导向的策略相结合的公司，将更有利于维持药物的可及性，并向支付方和医疗服务提供方证明其长期价值。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Eculizumab市场依适应症划分

  • 非典型溶血性尿毒症候群
    • 一线治疗
    • 二级治疗
  • 全身型重症肌无力
    • 不人道
    • 耐火
  • 视神经脊髓炎频谱障碍
    • 不人道
    • 耐火
  • 阵发性睡眠性血尿症
    • 一线治疗
    • 二级治疗

第九章 按通路分類的Eculizumab市场

  • 在线的
  • 离线

第十章 依最终用户分類的Eculizumab市场

  • 医院
    • 二级医疗机构
    • 三级医疗机构
  • 专科诊所
    • 血液科诊所
    • 神经内科诊所

第十一章 依病患年龄组别分類的Eculizumab市场

  • 成人版
  • 儿童
  • 老年人

第十二章 依Eculizumab市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章Eculizumab市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章Eculizumab市场（依国家划分）

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国Eculizumab市场

第十六章：中国Eculizumab市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Celltrion Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • UCB SA
Product Code: MRR-4F7A6D4FB6A3

The Eculizumab Market was valued at USD 4.35 billion in 2025 and is projected to grow to USD 4.53 billion in 2026, with a CAGR of 5.19%, reaching USD 6.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.35 billion
Estimated Year [2026] USD 4.53 billion
Forecast Year [2032] USD 6.21 billion
CAGR (%) 5.19%

Executive introduction to eculizumab's evolving role across complex complement-mediated disorders

Eculizumab has emerged as a defining biologic for complement-mediated conditions, and this executive introduction frames its clinical relevance, commercial dynamics, and strategic inflection points. The narrative highlights the therapy's mechanism as a terminal complement (C5) inhibitor and underscores how its clinical applications have expanded beyond hematology into neurology, creating new patterns of usage that cross traditional specialty boundaries. This context prepares stakeholders to interpret subsequent analyses with a clear understanding of the therapeutic's centrality to complex disease management.

Moreover, the introduction situates eculizumab within a larger ecosystem of next-generation complement inhibitors, long-acting formulations, and alternative complement-pathway approaches. It explains how these innovations interact with patient access pathways, hospital treatment protocols, and specialty clinic workflows. By presenting clinical developments alongside supply chain and reimbursement considerations, the introduction equips readers to appreciate downstream implications for clinical trial design, market access strategy, and manufacturing scale-up.

Finally, the introduction sets an analytical tone focused on practical implications rather than speculative forecasts. It emphasizes evidence-based evaluation of indications, distribution channels, and end-user behavior, thereby enabling executives to prioritize near-term actions and longer-term strategic pivots with confidence.

An in-depth view of scientific, regulatory, and competitive forces driving rapid transformation in the eculizumab treatment ecosystem

How recent scientific advances, treatment alternatives, and regulatory shifts are reshaping the competitive and clinical landscape for eculizumab

The landscape around eculizumab is undergoing transformative shifts driven by scientific innovation, competitive entrants, and evolving regulatory approaches. Advances in complement biology and the emergence of long-acting C5 inhibitors, along with agents targeting proximal complement components, are altering clinical decision-making by offering differentiated dosing frequency, administration setting, and safety profiles. As a result, clinicians increasingly weigh efficacy against treatment burden when selecting therapies for chronic complement-driven diseases.

In parallel, regulatory authorities have signaled greater openness to expedited pathways for therapies that address high unmet need, while also tightening post-approval surveillance expectations for rare disease indications. These regulatory dynamics have encouraged sponsors to pursue label expansions and real-world evidence programs that demonstrate long-term safety and functional outcomes. Simultaneously, payer scrutiny has intensified, prompting manufacturers to invest in value-based contracting and patient support infrastructures to sustain access.

Consequently, the competitive environment is shifting from a single-product focus to portfolio-level strategies that integrate clinical data, lifecycle management, and patient-centric services. This shift compels incumbent players to adapt commercial models, optimize channel strategies, and deepen engagement with specialty clinics and multidisciplinary care teams to retain clinical preference and payer support.

Evaluating the projected cumulative effects of United States tariff policy changes in 2025 on supply chain, manufacturing, and patient access for high-value biologics

The imposition of new or increased tariffs can ripple through the biologics value chain, affecting raw material sourcing, contract manufacturing costs, and logistics for therapies like eculizumab. Tariff-driven cost increases tend to manifest initially in higher procurement expenses for active pharmaceutical ingredients and specialized consumables, leading manufacturers to reassess supplier basins and near-shoring strategies. Over time, these pressures can accelerate investments in domestic manufacturing capacity or contractual hedges to stabilize input costs.

In addition, tariffs influence distribution economics by increasing landed costs of finished products and adding complexity to cross-border movement. Hospitals and specialty clinics may experience incremental administrative burdens as providers reconcile changes to procurement contracts and inventory management practices. Meanwhile, payers and health systems could intensify cost-containment efforts, potentially heightening demands for outcome-linked pricing arrangements or step-therapy policies that favor lower-cost alternatives when clinically appropriate.

Therefore, stakeholders should anticipate a period of operational recalibration in response to tariff-driven cost pressures. Manufacturers will likely explore supply chain de-risking, pricing adjustments in negotiated channels, and strengthened patient assistance programs to mitigate access disruption. Ultimately, the cumulative tariff impact will be mediated by contractual flexibility, manufacturing footprint, and the ability to demonstrate compelling clinical value that justifies continued access despite increased system costs.

Strategic segmentation insights synthesizing indication, distribution channel, end user, and patient age group dynamics to inform targeted commercial strategies

The market for eculizumab spans multiple indications, each with distinct clinical pathways and treatment paradigms. Atypical Hemolytic Uremic Syndrome is managed across first-line and second-line settings where early intervention versus refractory scenarios dictate different diagnostic workflows and support needs. Generalized Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder each present non-refractory and refractory subpopulations that require nuanced clinical decision-making, often involving neurologists with subspecialty expertise. Paroxysmal Nocturnal Hemoglobinuria similarly divides into first-line and second-line cohorts, where prior transfusion history and thrombotic risk shape treatment urgency and monitoring frequency.

Distribution channels further differentiate access and administration models, with hospital pharmacies-operating in secondary and tertiary hospitals-supporting inpatient and complex infusion scheduling, while retail pharmacies, comprising chain and independent outlets, play a role in outpatient dispensing, home infusion coordination, and patient education. End users reflect this channel complexity: hospitals and specialty clinics each have subgroups with specialized infrastructure, whereby secondary and tertiary hospitals manage acute, multi-disciplinary cases and hematology or neurology specialty clinics provide longitudinal care, infusion services, and adherence support.

Patient age group segmentation adds another layer of operational consideration. Adult patients split into 19-65 and over-65 cohorts, with geriatric patients often presenting comorbidities that affect dosing considerations and safety monitoring, whereas pediatric populations-adolescent and neonatal-require tailored formulations, weight-based dosing, and specialized caregiver support. Integrating these segmentation dimensions enables more precise targeting of clinical education, patient support services, channel optimization, and pricing strategies in order to align resources with the pathways that most influence uptake and sustained treatment.

Regional priorities and differentiated strategies across Americas, Europe, Middle East & Africa, and Asia-Pacific that shape access, regulatory engagement, and commercial execution

Regional dynamics exert a major influence on the diffusion of eculizumab therapies, with distinct regulatory frameworks, reimbursement mechanisms, and healthcare infrastructure shaping uptake. In the Americas, policy emphasis on rare disease access and established specialty care networks often facilitates concentrated use in tertiary centers, while payer negotiations and bundled purchasing arrangements shape commercial terms. Conversely, Europe, Middle East & Africa presents a diverse regulatory mosaic where country-level HTA processes, national reimbursement bodies, and variable hospital capabilities require tailored evidence dossiers and flexible pricing approaches to secure formulary placement.

In the Asia-Pacific region, rapid growth in specialty care capacity in urban centers contrasts with capacity constraints in rural areas, prompting manufacturers to prioritize partnerships with center-of-excellence sites and to invest in clinician education and diagnostic capability-building. Across all regions, evolving real-world evidence expectations and localized post-marketing surveillance influence launch sequencing and the design of observational studies intended to support reimbursement dossiers. Furthermore, regional supply chain resilience and local manufacturing policy considerations increasingly inform decisions about production siting and inventory strategies.

Consequently, manufacturers and service providers must adopt differentiated regional playbooks that combine regulatory intelligence, targeted clinical evidence generation, and nuanced payer engagement to navigate heterogeneous market access landscapes and to ensure consistent patient access across global regions.

Corporate positioning, partnership strategies, and lifecycle management approaches shaping competitive dynamics for eculizumab and adjacent complement-targeting therapies

Key company strategies reflect a dual focus on protecting incumbent franchises while investing in next-generation assets and strategic partnerships. The original innovator has concentrated on lifecycle extensions through label expansions, patient support programs, and long-term safety studies that reinforce clinical value, while also leveraging manufacturing scale and global distribution networks to maintain supply reliability. At the same time, a wave of companies pursuing alternative complement pathway targets and longer-acting C5 inhibitors have adopted complementary approaches, including co-development agreements, licensing deals, and targeted clinical programs focusing on subpopulations with high unmet need.

Partnerships with contract manufacturing organizations, logistics providers, and clinical centers of excellence are common as companies seek to optimize cold-chain integrity, reduce lead times, and strengthen post-marketing evidence collection. Additionally, corporate strategies increasingly emphasize integrated service offerings-linking therapy delivery with diagnostics, adherence monitoring, and outcomes tracking-to differentiate value propositions for payers and providers. Intellectual property timelines and biosimilar entrants further influence commercial tactics, prompting incumbent firms to reinforce brand value through real-world outcome data, specialized training for prescribers, and bundled care solutions that address total cost of care considerations.

These strategic moves collectively shape a landscape in which clinical differentiation, service integration, and manufacturing resilience determine competitive advantage more than product exclusivity alone.

Actionable recommendations for industry leaders to protect access, optimize commercial performance, and accelerate patient-centric innovation in complement therapeutics

Industry leaders should prioritize a three-pronged approach that combines clinical evidence expansion, supply chain resilience, and payer-aligned value communication. First, invest in targeted real-world evidence programs that document functional outcomes across key indications and subpopulations; this evidence will strengthen reimbursement negotiations and clinical adoption, particularly where comparative effectiveness questions arise. Second, de-risk supply chains by diversifying raw material suppliers, exploring localized manufacturing partnerships, and implementing inventory strategies that reduce vulnerability to tariff- or logistics-induced disruptions. These operational moves will preserve continuous access for hospitals and specialty clinics.

Third, develop payer-centric value propositions that extend beyond pricing to include outcomes-based contracts, patient support services, and adherence programs that demonstrably reduce long-term health system costs. In parallel, refine segmentation-based commercial tactics that match channel capabilities with patient needs, ensuring tertiary centers, specialty clinics, and outpatient infusion settings each receive tailored training and support. Finally, leaders should pursue collaborative initiatives with clinical networks to standardize diagnostic pathways and care algorithms, thereby reducing time-to-diagnosis and ensuring appropriate targeting of high-value therapies.

Taken together, these recommendations enable organizations to protect clinical access, sustain commercial performance, and accelerate innovations that deliver measurable benefits for patients and health systems.

Rigorous mixed-method research methodology integrating primary stakeholder interviews, secondary evidence synthesis, and contextual policy analysis to support robust conclusions

This study employs a mixed-methods approach combining structured primary research with comprehensive secondary analysis and contextual regulatory review. Primary research involved in-depth interviews with clinicians across hematology and neurology specialties, hospital pharmacy directors, specialty clinic leaders, and payers to capture real-world treatment pathways, access barriers, and channel preferences. These interviews were complemented by discussions with supply chain and manufacturing experts to understand logistics, cold-chain requirements, and capacity constraints.

Secondary evidence synthesis included peer-reviewed clinical literature, public regulatory documents, prescribing guidelines, and published safety and efficacy reports to create a validated clinical foundation for the analysis. The research team triangulated findings across sources to identify consistent themes and to highlight areas of divergence that warrant further investigation. Finally, policy and tariff analyses were conducted using official trade and regulatory publications, combined with scenario-based modeling of operational impacts to inform actionable recommendations. Quality assurance measures included expert review cycles and cross-functional validation to ensure the analysis reflects both clinical realities and commercial imperatives.

Concluding synthesis emphasizing strategic priorities for sustaining clinical access and long-term value for patients receiving complement inhibition therapies

In conclusion, eculizumab remains a clinically important therapy within a rapidly evolving therapeutic class characterized by scientific innovation, changing regulatory expectations, and competitive diversification. The confluence of new entrants, alternative complement-targeting mechanisms, and evolving payer expectations requires a proactive, evidence-driven approach to lifecycle management. Companies that combine robust real-world evidence generation with resilient manufacturing and tailored regional strategies will be best positioned to sustain access and justify long-term value to payers and providers.

Furthermore, operational responsiveness to supply chain pressures-including tariff-related cost shifts-will be critical to maintaining uninterrupted access for patients treated across hospitals and specialty clinics. Strategic investments in patient support, outcomes tracking, and collaborative care pathways can mitigate access risk while reinforcing clinical value. Ultimately, the most successful players will be those that integrate clinical differentiation with pragmatic commercial tactics, ensuring therapies reach the patients who will benefit most while aligning with system-level priorities for affordability and measurable outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Eculizumab Market, by Indication

  • 8.1. Atypical Hemolytic Uremic Syndrome
    • 8.1.1. First Line
    • 8.1.2. Second Line
  • 8.2. Generalized Myasthenia Gravis
    • 8.2.1. Non-Refractory
    • 8.2.2. Refractory
  • 8.3. Neuromyelitis Optica Spectrum Disorder
    • 8.3.1. Non-Refractory
    • 8.3.2. Refractory
  • 8.4. Paroxysmal Nocturnal Hemoglobinuria
    • 8.4.1. First Line
    • 8.4.2. Second Line

9. Eculizumab Market, by Distribution Channel

  • 9.1. Online
  • 9.2. Offline

10. Eculizumab Market, by End User

  • 10.1. Hospitals
    • 10.1.1. Secondary Hospitals
    • 10.1.2. Tertiary Hospitals
  • 10.2. Specialty Clinics
    • 10.2.1. Hematology Clinics
    • 10.2.2. Neurology Clinics

11. Eculizumab Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Pediatric
  • 11.3. Geriatric

12. Eculizumab Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Eculizumab Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Eculizumab Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Eculizumab Market

16. China Eculizumab Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Biogen Inc.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Catalyst Biosciences, Inc.
  • 17.14. Celltrion Inc.
  • 17.15. Janssen Pharmaceuticals, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.
  • 17.19. Regeneron Pharmaceuticals, Inc.
  • 17.20. Roche Holding AG
  • 17.21. Samsung Bioepis Co., Ltd.
  • 17.22. Sanofi SA
  • 17.23. Swedish Orphan Biovitrum AB
  • 17.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ECULIZUMAB MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ECULIZUMAB MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ECULIZUMAB MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ECULIZUMAB MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ECULIZUMAB MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ECULIZUMAB MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ECULIZUMAB MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ECULIZUMAB MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ECULIZUMAB MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ECULIZUMAB MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ECULIZUMAB MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ECULIZUMAB MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ECULIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)